About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker MIRM · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 13, 2026Expanded-Access Program for the Treatment of Chronic Hepatitis D With Brelovitug
NCT07922733 · Chronic Hepatitis, Delta Virus
Brelovitug
MIRM
Mirum Pharmaceuticals, Inc.
—Available——Registry ↗
Nov 13, 2026Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)
NCT06553768 · Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)
Maralixibat, Placebo
MIRM
Mirum Pharmaceuticals, Inc.
Phase 3Active, not recruiting90Jul 29, 2026Registry ↗
Nov 13, 2026Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)
NCT06193928 · Alagille Syndrome, Progressive Familial Intrahepatic Choles…
Livmarli, Livmarli
MIRM
Mirum Pharmaceuticals, Inc.
—Recruiting70Sep 20, 2028Registry ↗
Oct 27, 2026Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevi…
NCT07454837 · Chronic Hepatitis D
Brelovitug (BJT-778), Bulevirtide
MIRM
Mirum Pharmaceuticals, Inc.
Phase 2/3Recruiting120Aug 31, 2027Registry ↗
Oct 27, 2026A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infect…
NCT06907290 · Chronic Hepatitis D Infection
Brelovitug 300 mg, Brelovitug 900 mg
MIRM
Mirum Pharmaceuticals, Inc.
Phase 2/3Active, not recruiting150May 2029Registry ↗
Oct 19, 2026A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With…
NCT04663308 · Primary Sclerosing Cholangitis
Volixibat, Placebo
MIRM
Mirum Pharmaceuticals, Inc.
Phase 2Active, not recruiting182Feb 20, 2026Registry ↗
Oct 8, 2026A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta…
NCT07200908 · Chronic Hepatitis D Infection
Brelovitug 300 mg, Bulevirtide 2 mg and Brelovitug - 300 mg
MIRM
Mirum Pharmaceuticals, Inc.
Phase 3Recruiting172Jun 30, 2027Registry ↗
Oct 7, 2026A Study to Evaluate the Absorption, Distribution, Metabolism, and Excretion of [14C]-MRM-3379
NCT07712718 · Healthy Volunteers
[14C]-MRM-3379
MIRM
Mirum Pharmaceuticals, Inc.
Phase 1Completed7Jul 8, 2026Registry ↗
Sep 29, 2026Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)
NCT07209462 · Fragile X Syndrome
Low dose of MRM-3379, Middle Dose of MRM-3379
MIRM
Mirum Pharmaceuticals, Inc.
Phase 2Recruiting60Oct 2027Registry ↗
Sep 16, 2026MRX-901: An Open-label Study to Assess Safety and Tolerability of Maralixibat in Participants With…
NCT07823127 · Intrahepatic Cholestasis of Pregnancy
Maralixibat
MIRM
Mirum Pharmaceuticals, Inc.
Phase 2Not yet recruiting15Jan 12, 2029Registry ↗
Aug 25, 2026A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With…
NCT05050136 · Primary Biliary Cholangitis, PBC
Volixibat, Placebo
MIRM
Mirum Pharmaceuticals, Inc.
Phase 2Active, not recruiting333Jan 2027Registry ↗
Jul 31, 2026The REPLACE Registry for Cholbam® (Cholic Acid)
NCT03115086 · Bile Acid Synthesis Disorders
Cholbam
MIRM
Mirum Pharmaceuticals, Inc.
—Active, not recruiting55Jul 2038Registry ↗
Jun 29, 2026A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Inf…
NCT07298330 · Chronic Hepatitis D Infection
Brelovitug 300 mg, Brelovitug 900 mg
MIRM
Mirum Pharmaceuticals, Inc.
Phase 3Active, not recruiting80Aug 2026Registry ↗
Jun 23, 2026Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients Wit…
NCT07290257 · Alagille Syndrome, Progressive Familial Intrahepatic Choles…
Livmarli Oral Product
MIRM
Mirum Pharmaceuticals, Inc.
Phase 4Recruiting230Sep 22, 2030Registry ↗
Jun 23, 2026An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (P…
NCT04185363 · Progressive Familial Intrahepatic Cholestasis (PFIC)
Maralixibat
MIRM
Mirum Pharmaceuticals, Inc.
Phase 3Completed84Apr 23, 2025Registry ↗
Jun 2, 2026A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholesta…
NCT04729751 · Progressive Familial Intrahepatic Cholestasis, Alagille Syn…
Maralixibat
MIRM
Mirum Pharmaceuticals, Inc.
Phase 2Completed27Dec 17, 2024Registry ↗
Dec 8, 2025MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in S…
NCT04168385 · Cholestatic Liver Disease
Maralixibat
MIRM
Mirum Pharmaceuticals, Inc.
Phase 2Completed52Sep 4, 2024Registry ↗
Mar 19, 2025Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai
NCT04524390 · Biliary Atresia
Maralixibat, Placebo
MIRM
Mirum Pharmaceuticals, Inc.
Phase 2Completed75Nov 7, 2023Registry ↗
Oct 28, 2024Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)
NCT04270682 · CTX
Blinded CDCA 250 mg TID, Placebo
MIRM
Mirum Pharmaceuticals, Inc.
Phase 3Completed19Jul 13, 2023Registry ↗
Aug 6, 2024A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With…
NCT04718961 · Intrahepatic Cholestasis of Pregnancy
Volixibat, Placebo
MIRM
Mirum Pharmaceuticals, Inc.
Phase 2Terminated4Dec 7, 2022Registry ↗
Dec 11, 2023A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial In…
NCT03905330 · Progressive Familial Intrahepatic Cholestasis (PFIC)
Maralixibat, Placebo
MIRM
Mirum Pharmaceuticals, Inc.
Phase 3Completed93Sep 1, 2022Registry ↗
Oct 23, 2023Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment…
NCT02057718 · Progressive Familial Intrahepatic Cholestasis (PFIC)
LUM001 (Maralixibat)
MIRM
Mirum Pharmaceuticals, Inc.
Phase 2Completed33May 8, 2020Registry ↗
Oct 3, 2023Open Label, Continuation Study of Cholic Acid in Subjects With Inborn Errors of Bile Acid Synthesis
NCT01438411 · Bile Acid Synthesis Defect
Cholic Acid
MIRM
Mirum Pharmaceuticals, Inc.
Phase 3Completed53Jul 2016Registry ↗
Oct 3, 2023Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of…
NCT01115582 · Inborn Errors of Bile Acid Synthesis
Cholic acid
MIRM
Mirum Pharmaceuticals, Inc.
Phase 3Completed16Aug 2010Registry ↗
Oct 3, 2023Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid
NCT00007020 · Infantile Refsum's Disease, Zellweger Syndrome
Cholic Acids
MIRM
Mirum Pharmaceuticals, Inc.
Phase 3Completed85Dec 2009Registry ↗
Nov 19, 2021An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treat…
NCT02047318 · Alagille Syndrome
LUM001 (Maralixibat)
MIRM
Mirum Pharmaceuticals, Inc.
Phase 2Completed19Jun 17, 2020Registry ↗
Oct 20, 2021A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagil…
NCT04530994 · Alagille Syndrome
maralixibat
MIRM
Mirum Pharmaceuticals, Inc.
—Approved for marketing——Registry ↗
Jul 14, 2021Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants Wit…
NCT02160782 · Alagille Syndrome
LUM001 (Maralixibat), Placebo
MIRM
Mirum Pharmaceuticals, Inc.
Phase 2Completed31May 28, 2020Registry ↗
Jul 1, 2021An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treat…
NCT02117713 · Alagille Syndrome
LUM001 (Maralixibat)
MIRM
Mirum Pharmaceuticals, Inc.
Phase 2Completed34Jun 1, 2020Registry ↗
Nov 25, 2019Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)
NCT02787304 · Non-Alcoholic Steatohepatitis
SHP626, Placebo
MIRM
Mirum Pharmaceuticals, Inc.
Phase 2Terminated197Jul 27, 2018Registry ↗
May 1, 2019A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose
NCT02571192 · Non-Alcoholic Steatohepatitis
SHP626, 5.95 μCi RAD
MIRM
Mirum Pharmaceuticals, Inc.
Phase 1Completed8Oct 1, 2015Registry ↗
Apr 4, 2019Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and…
NCT02475317 · Healthy Volunteers
Placebo, Maralixibat
MIRM
Mirum Pharmaceuticals, Inc.
Phase 1Completed84Dec 1, 2015Registry ↗
Mar 29, 2019Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Chol…
NCT02061540 · Primary Sclerosing Cholangitis (PSC)
LUM001
MIRM
Mirum Pharmaceuticals, Inc.
Phase 2Completed27Feb 2016Registry ↗
Mar 28, 2019Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With…
NCT01903460 · Alagille Syndrome
LUM001, Placebo
MIRM
Mirum Pharmaceuticals, Inc.
Phase 2Completed20Feb 2015Registry ↗
Mar 27, 2019Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary…
NCT01904058 · PBC, Primary Biliary Cirrhosis
LUM001, Placebo
MIRM
Mirum Pharmaceuticals, Inc.
Phase 2Completed66Apr 2015Registry ↗
Mar 26, 2019Safety and Tolerability Study of SHP626 in Overweight and Obese Adults
NCT02287779 · Non-Alcoholic Steatohepatitis
SHP626, Placebo
MIRM
Mirum Pharmaceuticals, Inc.
Phase 1Completed84Jun 19, 2015Registry ↗
Mar 26, 2019Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome
NCT02057692 · Alagille Syndrome
LUM001, Placebo
MIRM
Mirum Pharmaceuticals, Inc.
Phase 2Completed37Nov 16, 2016Registry ↗
Mar 19, 2019An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Pr…
NCT02321306 · Primary Biliary Cirrhosis
LUM001
MIRM
Mirum Pharmaceuticals, Inc.
Phase 2Withdrawn0Dec 2017Registry ↗
Mar 18, 2019A Placebo-controlled Study of Maralixibat (SHP625) in Pediatric Subjects With Progressive Familial…
NCT03353454 · Progressive Familial Intrahepatic Cholestasis (PFIC)
Maralixibat, Placebo
MIRM
Mirum Pharmaceuticals, Inc.
Phase 3Withdrawn0Jun 15, 2020Registry ↗
Mar 18, 2019Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease
NCT02131623 · Alagille Syndrome, Progressive Familial Intrahepatic Choles…
MIRM
Mirum Pharmaceuticals, Inc.
—Completed23Mar 2015Registry ↗

40 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:51 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances